title: Same Data; Different Interpretations.
authors: Bishal Gyawali, Nobel Hospital, Sinamangal, Kathmandu, Nepal; Vinay Prasad, Oregon Health and Sciences University, Portland, OR.
authors: Bishal
authors: B
authors: Gyawali
authors: Bishal Gyawali, Nobel Hospital, Sinamangal, Kathmandu, Nepal; Vinay Prasad, Oregon Health and Sciences University, Portland, OR.
authors: Vinay
authors: V
authors: Prasad
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects; D000068258:Bevacizumab / Q000008:administration & dosage / Q000009:adverse effects; D001943:Breast Neoplasms / Q000188:drug therapy / Q000401:mortality; D000068818:Cetuximab / Q000008:administration & dosage / Q000009:adverse effects; D003627:Data Interpretation, Statistical; D018450:Disease Progression; D018572:Disease-Free Survival; D017277:Drug Approval / Q000706:statistics & numerical data*; D000068338:Everolimus / Q000008:administration & dosage / Q000009:adverse effects; D019317:Evidence-Based Medicine / Q000706:statistics & numerical data*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000401:mortality; D008495:Medical Oncology / Q000706:statistics & numerical data*; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000401:mortality; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects; D015203:Reproducibility of Results; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D047428:Protein Kinase Inhibitors; D000068258:Bevacizumab; D000068338:Everolimus; D017239:Paclitaxel; D000068818:Cetuximab